FDA Reopens Comment Period for Over-the-Counter Monograph User Fees, Holds Stakeholder Webinar

Summary

The FDA is extending the public comment period for a proposed user-fee program for nonprescription monograph drugs, while also hosting a webinar to update stakeholders on the progress of discussions between the agency and industry.